Compare Natera Inc. Common Stock (NTRA) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Rocket Lab USA Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Rocket Lab USA Inc trades at $53.66 (market cap $41.06B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Rocket Lab USA Inc for 29 Days on average.
| NTRA | RKLB | |
|---|---|---|
Market Cap | $57.03B | $41.06B |
Volume | 1,131,157 | 15,510,966 |
Sector | Health | Industrials |
52-Week High | $425.64 | $150.23 |
52-Week Low | $179.42 | $39.48 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $56.18B | $38.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Rocket Lab (RKLB) trades at $64.22, down 2.27% today, amid bearish technical signals despite strong analyst support. The company recently secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. Financially, RKLB shows robust revenue growth ($602M in 2025, $769M projected for 2026) but remains unprofitable with a net income margin of -21.51%. Valuation metrics appear elevated with a P/S ratio of 48.79.
The outlook balances significant growth potential from a expanding launch backlog against persistent profitability challenges and competitive threats from SpaceX. Analyst consensus is strongly bullish with a $107 price target, but investors face risks from cash burn, execution hurdles, and high valuation multiples. The stock's near-term direction will hinge on Neutron rocket development and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
